COMP <GO>
ARQT vs JNJ // RSI-14 & 200D SMA MOMENTUM
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ARQT 5
— JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ARQT
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
rsi-technicals
66.3
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 67.90% | +22.30 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | 25.50% | -28.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 2.97% | -3.13 | JNJ | /fcf-yield <GO> |
| Operating Margin | -3.30% | 34.70% | -38.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 28.50% | -32.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 6.00% | +85.30 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 5.59 | +2.19 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | ARQT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 66.3 | 60.4 | +5.99 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 23.0x | +1.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $662.49B | -$658.47B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | JNJ REV | ARQT GROSS % | JNJ GROSS % | ARQT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $94.19B | 90.2% | 67.9% | -$6.3M | $19.70B |
| FY 2024 | $196.5M | $88.82B | 90.3% | 69.1% | -$112.3M | $19.84B |
| FY 2023 | $59.6M | $85.16B | 44.0% | 44.0% | -$249.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
JNJ // BETA 1.08